LOADING

Singapore biotech firm to begin human clinical trial for COVID-19 treatment

A Singapore-based biotechnology firm will begin human clinical trials next week for a potential monoclonal antibody treatment for COVID-19 that could slow down the progression of the disease in patien..

More

Biotech launches programme to help mitigate spread of viruses

Orgenesis’ BioShield Program has been designed to increase the level of preparedness to fight against emerging outbreaks and help avoid a global pandemic. The programme will combine different technolo..

More

Uniting human, animal pharma/biotech strengthens fight against cancer

Using a One Health approach to enhance developments for human and canine cancer treatments is central to a new manuscript, supported by World Small Animal Veterinary Association (WSAVA’s) One Health C..

More

Post-pandemic beauty: Blockchain and biotech set to thrive as safety fears soar, says expert

The ongoing coronavirus (COVID-19) crisis has accelerated and morphed consumer trends, catapulting safety and hygiene to the fore and increasing the relevance of blockchain and biotech in beauty, says..

More
Post-pandemic beauty: Blockchain and biotech set to thrive as safety fears soar, says expert

The ongoing coronavirus (COVID-19) crisis has accelerated and morphed consumer trends, catapulting safety and hygiene to the fore and increasing the relevance of blockchain and biotech in beauty, says..

More
USDA releases overhaul of biotech regulations

U.S. Secretary of Agriculture Sonny Perdue announced May 14 a final rule updating and modernizing the U.S. Department of Agriculture’s biotechnology regulations under the Plant Protection Act. The new..

More
Sanofi teams up with China biotech Alphamab for breast cancer R&D

French Big Pharma Sanofi, looking to bolster its cancer R&D, has penned a new pact with Alphamab Oncology that focuses on HER2-positive breast cancer.  

More
Why Gilead Sciences Stock is Fading

In barely a month when its shares topped $85 in April, Gilead Sciences (NASDAQ:GILD) is fading. Investors moved on to the next COVID-19 play, including Moderna (NASDAQ:MRNA), Novavax (NVAX), and Dynav..

More